Jacques Bogart Valuation

Q: What is the Fair Price of 0R9Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0R9Q (€5.98) is trading above our estimate of [[fair value]] (€4.12)

Is 0R9Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0R9Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0R9Q (€5.98) is trading above our estimate of fair value (€4.12)

Significantly Below Fair Value: 0R9Q is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0R9Q?

Key metric: As 0R9Q is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0R9Q. This is calculated by dividing 0R9Q's market cap by their current earnings.
What is 0R9Q's PE Ratio?
PE Ratio	9.6x
Earnings	€9.12m
Market Cap	€87.87m

0R9Q key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1x
Enterprise Value/EBITDA	-61x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 0R9Q's PE Ratio compare to its peers?

The above table shows the PE ratio for 0R9Q vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	30.3x
VLG Venture Life Group	65.1x	67.1%	UK£48.3m
APN Applied Nutrition	25.3x	n/a	UK£345.0m
W7L Warpaint London	25.3x	11.8%	UK£433.8m
MCB McBride	5.6x	-0.2%	UK£185.4m
0R9Q Jacques Bogart	9.6x	n/a	€87.9m

Price-To-Earnings vs Peers: 0R9Q is good value based on its Price-To-Earnings Ratio (9.6x) compared to the peer average (30.3x).

Price to Earnings Ratio vs Industry

How does 0R9Q's PE Ratio compare vs other companies in the European Personal Products Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 0R9Q is good value based on its Price-To-Earnings Ratio (9.6x) compared to the European Personal Products industry average (22.3x).

Price to Earnings Ratio vs Fair Ratio

What is 0R9Q's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0R9Q PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	9.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 0R9Q's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Gr. Sarantis

€690.1m

Produces and trades cosmetics, household, and parapharmaceutical products.

0IIO

€10.77

1.6%

33.8%

Ontex Group

€658.1m

Develops, produces, and supplies personal hygiene products and solutions for baby, feminine, and adult care in Belgium, the United Kingdom, the United States, Italy, France, and internationally.

0QVQ

€8.10

7.9%

15.3%

McBride

UK£185.4m

Manufactures and sells private label household and personal care products to retailers and brand owners in the United Kingdom, Germany, France, Italy, Spain, rest of Europe, Asia-Pacific, and internationally.It operates through five segments: Liquids, Powders, Unit dosing, Aerosols, and Asia Pacific.

MCBL

UK£1.07

4.9%

65.1%